Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 3Completed 2Recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 22Stomach Neoplasms 20Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 9Nasopharyngeal Carcinoma 5Lung Neoplasms 5Esophageal Squamous Cell Carcinoma 5Small Cell Lung Carcinoma 4Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Lymphoma, Extranodal NK-T-Cell 3Liver Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Carcinoma 3Nonsquamous Non-Small Cell Lung Cancer 2Nasopharyngeal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Neuroendocrine 2Advanced Biliary Tract Cancer 2Unresectable Locally Advanced Pancreatic Cancer 1Triple Negative Breast Neoplasms 1Tislelizumab 1Thoracic Neoplasms 1Thoracic Malignancies 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Respiratory Tract Diseases 1Recurrent/ Advanced Stage Endometrial Cancer Patients 1

Interventions

Gemcitabine 13Oxaliplatin 9Capecitabine 6lenvatinib 5apatinib 5Cisplatin 5tislelizumab 4Surgical Procedures, Operative 4Radiofrequency Ablation 4Neoadjuvant Therapy 4Fluorouracil 4toripalimab 3sintilimab 3Radiotherapy 3Leucovorin 3Irinotecan 3regorafenib 2pembrolizumab 2durvalumab 2camrelizumab 2Stents 2Photochemotherapy 2Immunotherapy 2Hepatectomy 2Folfox protocol 2Everolimus 2Drug Therapy 2Cholangiopancreatography, Endoscopic Retrograde 2Blood Specimen Collection 21-phenyl-3,3-dimethyltriazene 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Cholangiocarcinoma × sintilimab × Clear all
NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

NCT05251662 2022-02-23

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
90 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05207735 2022-01-26

SCRCA

Henan Cancer Hospital

Phase 2 Unknown
73 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡